Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2008

View Archived Issues

Significant treatment effect seen with gepirone ER in depression studies

Link between metabotropic glutamate receptor and fragile X syndrome seen in mice

Brain cholesterol reduction with LXR agonist beneficial in experimental Niemman-Pick disease

Recent patents report novel anticancer agents

BioMarin and Genzyme restructure their joint venture for Aldurazyme for MPS I

Novel therapeutic compounds for metabolic disorders described in recent patent literature

Innocoll initiates dosing in U.S. phase II clinical trial of CollaRx bupivacaine surgical implant

Multifunctional serotonin receptor modulator suppresses psychosis and appetite in mice

Astellas Pharma reports third quarter 2007 results

Recent patents disclose new psychopharmacologic drugs

Pfizer and Taisho sign definitive agreement for novel schizophrenia drug candidate

Access acquires Somanta and adds four new anticancer compounds to pipeline

Biogen and Elan report on Tysabri safety in MS patients

Celldex receives fast track designation for glioblastoma vaccine CDX-110

Jazz Pharmaceuticals receives orphan drug designation for acute repetitive seizures candidate

Optimer awarded NIH grant to develop OPT-80 for hospital-associated infection

Orphan drug designation granted for non-radiolabeled TM-601

Sangamo initiates phase II clinical trial of SB-509 in diabetic neuropathy

Metabasis reports positive results from phase Ib clinical trial of MB-07811 for hyperlipidemia

R-7128 achieves rapid virologic response in 4-week combination study for HCV

Rib-X initiates two phase II studies of oxazolidinone antibiotic RX-1741 for CAP and uSSSI

Callisto restructures license agreement with Genzyme for atiprimod for carcinoid cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...